ORIGINAL PAPER
COVID-19 associated mucormycosis in head and neck region of children during current pandemic: Our experiences
1
Department of Otorhinolaryngology, IMS and SUM hospital, Siksha “O” Anusandhan University, Odisha, India
2
Department of Microbiology, IMS and SUM hospital, Siksha “O” Anusandhan University, Odisha, India
Submission date: 2021-05-17
Final revision date: 2021-06-15
Acceptance date: 2021-06-17
Publication date: 2021-09-29
Pediatr Pol 2021;96(3):162-167
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Mucormycosis is a rare but severe fungal infection, particularly found in immunocompromised patients. Currently this dreaded mucormycosis is rising among COVID-19 paediatric patients during their treatment period or after their discharge from hospital. It is also called as black fungus. The aim of this study is to evaluate the COVID-19 associated mucormycosis (CAM) in head and neck region of the paediatric patients with its clinical manifestations and management.
Material and methods:
This is a descriptive and prospective study of paediatric patients with COVID-19 associated mucormycosis (CAM) carried out at a postgraduate teaching hospital. This study was conducted between March 2020 to April 2021. Patient profile such as age, sex, comorbidities, clinical presentations, diagnosis and treatment of the CAM were analysed. There were 12 paediatric patients of CAM were enrolled in this study.
Results:
Out of 12 paediatric patients of CAM, there were eight male and four female patients, aged from 3 years to 16 years. Out of the 12 patients, 3 were diabetic (25%). Three patients (25%) were taking prolonged systemic steroids with prolonged hospital ICU stay. Two children (16.66%) were under chemotherapy for acute leukaemia. The common clinical symptoms were facial swelling, facial pain, nasal block and nasal discharge. Diagnosis was confirmed by histological examination. All were treated with endoscopic surgical debridement and amphotericin B. Two patients were passed away; one was due to cerebral involvement and another was due to respiratory failure by pneumonia.
Conclusions:
Early identification and prompt treatment in paediatric patients with CAM are required. Aggressive endoscopic surgical debridement for local control and appropriate systemic antifungal treatment will help to improve the prognosis and survival of the patients.
Mucormycosis is a rare but severe fungal infection, particularly found in immunocompromised patients. Currently this dreaded mucormycosis is rising among COVID-19 paediatric patients during their treatment period or after their discharge from hospital. It is also called as black fungus. The aim of this study is to evaluate the COVID-19 associated mucormycosis (CAM) in head and neck region of the paediatric patients with its clinical manifestations and management.
Material and methods:
This is a descriptive and prospective study of paediatric patients with COVID-19 associated mucormycosis (CAM) carried out at a postgraduate teaching hospital. This study was conducted between March 2020 to April 2021. Patient profile such as age, sex, comorbidities, clinical presentations, diagnosis and treatment of the CAM were analysed. There were 12 paediatric patients of CAM were enrolled in this study.
Results:
Out of 12 paediatric patients of CAM, there were eight male and four female patients, aged from 3 years to 16 years. Out of the 12 patients, 3 were diabetic (25%). Three patients (25%) were taking prolonged systemic steroids with prolonged hospital ICU stay. Two children (16.66%) were under chemotherapy for acute leukaemia. The common clinical symptoms were facial swelling, facial pain, nasal block and nasal discharge. Diagnosis was confirmed by histological examination. All were treated with endoscopic surgical debridement and amphotericin B. Two patients were passed away; one was due to cerebral involvement and another was due to respiratory failure by pneumonia.
Conclusions:
Early identification and prompt treatment in paediatric patients with CAM are required. Aggressive endoscopic surgical debridement for local control and appropriate systemic antifungal treatment will help to improve the prognosis and survival of the patients.
REFERENCES (35)
1.
Zaoutis TE, Roilides E, Chiou CC, etc. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-727.
2.
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020; 8: 475-481.
3.
Swain SK, Jena PP. Clinical implications and future perspective of COVID-19 pandemic – a review. Int J Adv Med 2021; 8: 334-340.
4.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273.
5.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health 2020; 25: 278-280.
6.
Broughton JP, Deng X, Yu G, et al. CRISPR – Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020; 38: 870-874.
7.
Swain SK, Acharya S, Sahajan N. Otorhinolaryngological manifestations in COVID-19 infections: An early indicator for isolating the positive cases. J Sci Soc 2020; 47: 63-68.
8.
Swain SK, Das S, Padhy RN. Performing tracheostomy in intensive care unit-A challenge during COVID-19 pandemic. Siriraj Medical Journal 2020; 72: 436-442.
9.
Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185: 599-606.
10.
Rodden M, Zaoutis T, Buchanan W, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
11.
Cornely OA, Alastruey-Izquierdo A, Arnez D, et al. Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study group Education and Research Consortium. Lancet Infect Dis 2019; 19: 405-421.
12.
Sharma MC, Gill SS, Kashyap S, et al. Gastrointestinal mucormycosis – an uncommon isolated mucormycosis. Indian J Gastroenterol 1998; 17: 131-133.
15.
Elitzur S, Arad-Cohen N, Barg A, et al. Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. Br J Haematol 2020; 189: 339-350.
16.
Kennedy KJ, Daveson K, Slavin MA, et al. Australia and New Zealand Mycoses Interest Group of the Australasian Society for Infectious Diseases. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect 2016; 22: 775-781.
17.
Skiada A, Pagano L, Groll A, et al; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-1867.
18.
Pana ZD, Seidel D, Skiada A, et al. Collaborators of Zygomyco.net and/or FungiScope Registries. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis 2016; 16: 667.
19.
Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54:.
21.
Swain SK, Behera IC, Mohanty JN. Mucormycosis in head-and-neck region – Our experiences at a tertiary care teaching hospital of Eastern India. Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery 2019; 3: 58-62.
22.
Swain SK, Sahu MC, Banerjee A. Non-sinonasal isolated facio-orbital mucormycosis – A case report. J Mycol Med 2018; 28: 538-541.
23.
Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19. Indian.
25.
Swain SK, Sahu MC, Baisakh MR. Mucormycosis of the Head and Neck. Apollo Medicine 2018; 15: 6-10.
26.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 5.
27.
Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India:epidemiology, diagnosis and treatment. Med Mycol 2019; 57: 395-402.
28.
Lumbang WA, Caufield BA. Vesicular eruption on the arm of an infant. Dermatol Online J 2010; 16: 13.
29.
Sandeep P, Dave MD, Richard J, et al. Facial cutaneous mucormycosis in a full-term infant. Arch Otolaryngol Head Neck Surg 2008; 134: 206-209.
30.
Khan ZU, Ahmad S, Brazda A, et al. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to pasoconazole. J Clin Microbiol 2009; 47: 1244-1248.
31.
Abedi E, Sismanis A, Choi K, et al. Twenty-five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope1984; 94: 1060-1062.
32.
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264.e5-264.e8.
33.
Antoniadi K, Iosifidis E, Vasileiou E, et al. Invasive Mucormycosis in Children With Malignancies: Report From the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology. Chemotherapy 2020; 2: 5-15.
34.
Styczynski J, Czyżewski K, Frączkiewicz J, et al. Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010-2019. Acta Haematol Pol 2020; 51: 157-163.
35.
Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG); International Immunocompromised Host Society (ICHS); European Leukaemia Net (ELN). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15: 327-340.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
